Skip to main content

Advertisement

Table 5 GRADE evidence profile for impact of NMBA in acute ARDS from systematic review and meta-analysis of randomized controlled trials

From: Neuromuscular blocking agents in patients with acute respiratory distress syndrome: a summary of the current evidence from three randomized controlled trials

No of studies (No of participants)   Quality assessment Summary of findings
   Study limitations Consistency Directness Precision Publication bias Relative effect (95% CI) Best estimate of intervention group Quality
     NMBA vs. Control      
ICU Mortality:
3 (431) Moderate limitations* No important inconsistency Direct Not important imprecision Unlikely   0.71 (0.55 – 0.90) 27% +++, moderate
Mortality at Day 28:
2 (395) Moderate limitations* No important inconsistency Direct Not important imprecision Unlikely   0.68 (0.51 – 0.92) 23.7% +++, moderate
Barotrauma:
3 (431) Moderate limitations* No important inconsistency Direct Not important imprecision Unlikely   0.45 (0.22 – 0.92) 0% +++, moderate
Critical illness neuromyopathy:
3 (293) Moderate limitations* No important inconsistency Direct Not important imprecision Unlikely   1.13 (0.76 – 1.67) 0% +++, moderate
  1. *Unclear allocation concealment in two studies, not analyzed using intention-to-treat in one studies.